Molecular Oncology
Volume 4, Issue 5 , Pages 443-450, October 2010

Targeting leukemic stem cells by breaking their dormancy

HI-STEM (Heidelberg Institute for Stem Cell Technology and Experimental Medicine), Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany

Received 4 May 2010; received in revised form 1 June 2010; accepted 1 June 2010. published online 14 June 2010.

Abstract 

Transient or long-term quiescence, the latter referred to as dormancy are fundamental features of at least some adult stem cells. The status of dormancy is likely a critical mechanism for the observed resistance of normal HSCs and leukemic stem cells (LSCs) to anti-proliferative chemotherapy. Recent studies have revealed cytokines such as Interferon-alpha (IFNα) and G-CSF as well as arsenic trioxide (As2O3) to be efficient agents for promoting cycling of dormant HSCs and LSCs. Most interestingly, such cell cycle activated stem cells become exquisitely sensitive to killing by different chemotherapeutic agents, suggesting that dormant LSCs in patients may be targeted by a sequential two-step protocol involving an initial activation by IFNα, G-CSF or As2O3, followed by targeted chemotherapy.

Keywords: Stem cells, Leukemia, Therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(10)00047-5

doi:10.1016/j.molonc.2010.06.001

Molecular Oncology
Volume 4, Issue 5 , Pages 443-450, October 2010

Article Tools

* Image Usage & Resolution